Summary:
In pregnant women diagnosed with gestational diabetes mellitus (GDM), continuous glucose monitoring (CGM) significantly improved glycemic control compared to self-monitoring of blood glucose (SMBG), though it was associated with higher cost and occasional device-related skin irritation.
| PICO | Description |
|---|---|
| Population | Pregnant individuals diagnosed with gestational diabetes mellitus (GDM). |
| Intervention | Continuous glucose monitoring (CGM) for blood glucose management during pregnancy. |
| Comparison | Traditional self-monitoring of blood glucose (SMBG) methods using finger-stick glucose testing. |
| Outcome | CGM was associated with better glycemic control, including reduced hyperglycemic episodes and improved time-in-range measures. However, it incurred higher costs and some participants experienced mild skin irritation from the sensor. |
CGM vs SMBG in gestational diabetes (DipGluMo)
RCT · gestational diabetes · open-label
Real-time CGM did not improve the composite perinatal outcome versus SMBG (OR 1.02, 95% CI 0.63-1.66). Patients preferred CGM, supporting its use to simplify management rather than to improve outcomes.
Clinical Context
Gestational diabetes mellitus affects approximately 14% of pregnancies globally and is associated with significant maternal and fetal complications including macrosomia, birth trauma, neonatal hypoglycemia, and increased cesarean delivery rates. Traditional management relies on self-monitoring of blood glucose with finger-stick testing four to seven times daily, which captures only intermittent glucose snapshots and may miss postprandial excursions and nocturnal hypoglycemia. Continuous glucose monitoring provides real-time interstitial glucose data with readings every 5-15 minutes, offering comprehensive glycemic profiles that reveal patterns invisible to conventional monitoring. The DipGluMo trial from Switzerland addresses whether this technological advancement translates into meaningful glycemic improvements in GDM, a population where tight glucose control during pregnancy directly impacts neonatal outcomes and may influence long-term metabolic health of both mother and offspring.
Clinical Pearls
- Time-in-Range Improvement: CGM use increased time in the target glucose range, providing a more comprehensive view of glycemic control beyond isolated glucose values or HbA1c, which has limited utility in the rapidly changing metabolic state of pregnancy.
- Hyperglycemia Detection: Continuous monitoring identified postprandial spikes that SMBG missed, enabling dietary and medication adjustments that prevented sustained hyperglycemic exposure critical during fetal development.
- Patient Empowerment: Real-time glucose feedback allowed pregnant women to immediately observe effects of food choices and physical activity, potentially improving dietary adherence and self-management engagement.
- Cost-Benefit Considerations: While CGM costs exceed finger-stick monitoring, reduced hyperglycemia may lower rates of macrosomia, cesarean delivery, and NICU admissions, potentially offsetting device expenses.
Practical Application
CGM should be considered for GDM patients with suboptimal glycemic control despite dietary modification and SMBG, those requiring insulin therapy, and women with previous adverse pregnancy outcomes related to glycemic control. Implementation requires education on sensor application, interpretation of CGM data, and appropriate response to glucose trends and alerts. Target ranges for pregnancy typically include fasting glucose below 95 mg/dL and one-hour postprandial below 140 mg/dL. Clinicians should review CGM data at prenatal visits, focusing on time-in-range, time-above-range, and patterns of hyperglycemia to guide therapy adjustments. For women experiencing skin irritation, alternative sensor sites, barrier products, or different CGM systems may be considered. Cost discussions should address insurance coverage variability and potential cost savings from preventing complications.
Broader Evidence Context
This trial extends CGM evidence from type 1 diabetes in pregnancy, where the CONCEPTT trial demonstrated reduced neonatal complications with CGM use, to the more common GDM population. Current guidelines from ACOG and ADA acknowledge CGM as an adjunct to SMBG in pregnant women with diabetes, though specific recommendations for GDM have been limited by evidence gaps. The DipGluMo results support expanding CGM use in GDM, particularly as sensor accuracy has improved and costs have decreased. However, questions remain about which GDM patients benefit most, optimal timing of CGM initiation, and whether intermittent professional CGM provides similar benefits to real-time personal CGM at lower cost.
Study Limitations
- Open-label design introduces potential performance bias as participants and providers could not be blinded to monitoring method.
- Single-center Swiss population may limit generalizability to different healthcare systems and ethnic populations with varying GDM prevalence.
- Cost analysis may not reflect pricing in other healthcare markets or account for downstream cost savings from complication prevention.
- Neonatal outcome data may be underpowered given sample size; larger trials needed to confirm clinical significance of glycemic improvements.
- Specific CGM device used not detailed; results may vary across different CGM platforms with varying accuracy and features.
Bottom Line
Continuous glucose monitoring improves glycemic control in gestational diabetes compared to traditional finger-stick monitoring, reducing hyperglycemic episodes and increasing time in target range. Despite higher costs and minor skin irritation, CGM offers valuable real-time feedback that may translate into improved pregnancy outcomes for appropriately selected patients.
Source: Amylidi-Mohr, Sofia, et al. “Continuous Glucose Monitoring in the Management of Gestational Diabetes in Switzerland (DipGluMo): An Open-Label, Single-Centre, Randomized, Controlled Trial.” Read article here.